The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
- 1 August 2007
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 110 (3), 972-978
- https://doi.org/10.1182/blood-2007-01-067769
Abstract
To define prognostic impact of Epstein-Barr virus (EBV) infection in diffuse large B-cell lymphoma (DLBCL), we investigated EBV status in patients with DLBCL. In all, 380 slides from paraffin-embedded tissue were available for analysis by EBV-encoded RNA-1 (EBER) in situ hybridization, and 34 cases (9.0%) were identified as EBER-positive. EBER positivity was significantly associated with age greater than 60 years (P = .005), more advanced stage (P < .001), more than one extranodal involvement (P = .009), higher International Prognostic Index (IPI) risk group (P = .015), presence of B symptom (P = .004), and poorer outcome to initial treatment (P = .006). The EBER+ patients with DLBCL demonstrated substantially poorer overall survival (EBER+ vs EBER− 35.8 months [95% confidence interval (CI), 0-114.1 months] vs not reached, P = .026) and progression-free survival (EBER+ vs EBER− 12.8 months [95% CI, 0-31.8 months] vs 35.8 months [95% CI, 0-114.1 months], respectively (P = .018). In nongerminal center B-cell–like subtype, EBER in situ hybridization positivity retained its statistical significance at the multivariate level (P = .045). Nongerminal center B-cell–like patients with DLBCL with EBER positivity showed substantially poorer overall survival with 2.9-fold (95% CI, 1.1-8.1) risk for death. Taken together, DLBCL patients with EBER in situ hybridization+ pursued more rapidly deteriorating clinical course with poorer treatment response, survival, and progression-free survival.Keywords
This publication has 30 references indexed in Scilit:
- Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) studyBlood, 2006
- Epstein–Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B‐cell lymphomaCancer Science, 2006
- Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based StudyJournal of Clinical Oncology, 2005
- Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based studyBlood, 2005
- Microarray-based classification of diffuse large B-cell lymphomaEuropean Journal of Haematology, 2005
- Biology and Treatment of Epstein-Barr Virus–Associated Non-Hodgkin LymphomasHematology, 2005
- Epstein-Barr virus: exploiting the immune systemNature Reviews Immunology, 2001
- The Characteristics of Epstein‐Barr Virus (EBV)‐positive Diffuse Large B‐Cell Lymphoma: Comparison between EBV+ and EBV‐ Cases in Japanese PopulationJapanese Journal of Cancer Research, 2000
- Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell deathCell, 1991
- SELECTIVE TRANSFORMATION OF B LYMPHOCYTES BY E.B. VIRUSThe Lancet, 1973